SCHEMBL5760427

SCHEMBL5760427

Cc1ccc(NS(=O)(=O)c2ccc(Cc3ccc4oc(=O)cc(C(F)(F)F)c4c3)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.48
MAPT P10636 3/20 0.48
FFAR4 Q5NUL3 3/20 0.48
ALDH1A1 P00352 4/20 0.47
GAA P10253 3/20 0.47
GLA P06280 2/20 0.47
PKM P14618 2/20 0.47
POLB P06746 1/20 0.47
ERAP1 Q9NZ08 1/20 0.47
AR P10275 1/20 0.46
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
TRPC3 Q13507 1/20 0.44
HPGD P15428 3/20 0.43
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5760245 0.92 KMT2A (0.55) KDM4EMAPTFFAR4ALDH1A1GAA
SCHEMBL5759426 0.91 PKM (0.53) KDM4EMAPTFFAR4ALDH1A1GAA
SCHEMBL5763574 0.90 HTT (0.50) KDM4EFFAR4ALDH1A1GAAGLA
SCHEMBL5860039 0.90 PKM (0.43) KDM4EFFAR4ALDH1A1GAAGLA
SCHEMBL5761750 0.90 KDM4E (0.46) KDM4EFFAR4ALDH1A1GAAGLA
SCHEMBL5761019 0.89 AR (0.48) KDM4EMAPTFFAR4ALDH1A1GAA
SCHEMBL5762929 0.89 HDAC4 (0.46) KDM4EMAPTFFAR4ALDH1A1GAA
SCHEMBL5860303 0.88 PKM (0.41) KDM4EMAPTFFAR4ALDH1A1GAA
SCHEMBL5762376 0.88 PKM (0.41) KDM4EMAPTFFAR4ALDH1A1GAA
SCHEMBL5762259 0.88 ALDH1A1 (0.49) KDM4EALDH1A1GAAARMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT KDM4E 870/4885MAPT 3579/4885FFAR4 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.